Tag: Cancer: Leukemia
Ibrutinib-Rituximab Beats Chemoimmunotherapy for CLL
Progression-free, overall survival improved in the ibrutinib-rituximab group at three years
Anesthesia Tied to Neurocognitive Impairment in Childhood ALL Survivors
Survivors experience impairment with exposure to propofol, fluranes, longer anesthesia duration
High Response Seen for Chemo in Seniors With High-Risk AML
Complete response rate for patients treated with chemo was 69 percent; three-year OS was 21 percent
Gait Speed Is Prognostic in Older Patients With Blood Cancer
Decrease in gait speed linked to higher mortality, increased odds of unplanned hospitalization, ED use
Allo-HCT With Unrelated Donor Tied to Better Outcomes in AML
In active AML, outcomes superior for allo-HCT with unrelated donor than for cord blood transplantation
ASCO: Combo Regimen Effective in CLL With Coexisting Conditions
Progression-free survival longer with venetoclax-obinutuzumab versus chlorambucil-obinutuzumab
Ibrutinib, Venetoclax Active in High-Risk, Seniors With CLL
Findings seen in phase 2 study of combo regimen for first-line treatment of chronic lymphocytic leukemia
Octogenarians With Acute Myeloid Leukemia Have Poor Survival
Overall survival 1.5 months; survival improved for those receiving chemotherapy
FDA Approves Venetoclax for Chronic Lymphocytic Leukemia
In randomized trial, drug demonstrated statistically significant improvement in progression-free survival
FDA Approves Venetoclax for Chronic, Small Lymphocytic Leukemia
In randomized trial, drug demonstrated statistically significant improvement in progression-free survival
